06 / Applications
Starting with platelets. Built for the whole blood ecosystem.
Lead program
Platelets
~2.6 million platelet units are distributed annually in the U.S. Short shelf life, fragmented blood-type inventories and frequent ABO-non-identical use create a significant need for greater interchangeability.
Trauma
Shortages
Pediatrics
Transplant
Other high-need settings
Plasma
~1.9 million plasma units are transfused annually in the U.S. HemoDefend has been extensively evaluated in plasma, with significant anti-A/anti-B reduction while preserving coagulation activity and product quality.
Whole blood
The same affinity technology has been evaluated in whole blood, including with Hoxworth Blood Center, as a way to expand the low-titer Type O donor pool.
Plasma processing
An important longer-term platform opportunity where ABO antibodies constrain downstream plasma products.
Additional potential applications
Freeze-dried plasma
Military & emergency medicine
International blood systems
Other blood & plasma-processing applications
03 / Platform
One technology. Multiple blood products.
The same core affinity technology addresses ABO antibody compatibility across the blood ecosystem. Platelets are the initial intended commercial focus, subject to successful development and regulatory authorization; plasma, whole blood and plasma processing are additional platform opportunities.
Initial commercial focus
Platelets
Extensively evaluated
Plasma
Evaluated
Whole blood
Longer-term opportunity
Plasma processing
Potential future
Freeze-dried plasma
Military & emergency medicine
International blood systems
09 / Partner with us
Build the next stage with us.
We welcome discussions with blood centers, strategic partners, plasma processors, potential investors and biomedical collaborators on:
Blood-center collaboration
Strategic partnerships
Research & development
Plasma-processing applications
Investment
Business development